Sorrell v. IMS Health Inc.
Headline: Vermont law banning sale and use of doctors’ prescription data for marketing is struck down, enabling drug companies and data brokers to use prescriber-identifying records and limiting state restrictions on pharmaceutical marketing.
Holding: The Court held that Vermont’s statute imposing a broad ban on selling or using doctors’ prescribing records for marketing is a content- and speaker-based restriction that fails heightened First Amendment scrutiny and is unconstitutional.
- Blocks states from broadly banning sale or marketing use of prescriber-identifying records.
- Allows drug companies and data brokers to buy and use doctors’ prescribing data for marketing.
- Forces states to adopt narrower privacy or disclosure rules if they want to limit marketing.
Summary
Background
Vermont passed a law (Act 80, §4631(d)) that largely barred pharmacies, insurers, and others from selling, disclosing, or permitting use of records showing individual doctors’ prescribing habits for marketing unless the doctor consents. The law included exceptions for research, insurers, patient care, and certain state programs. Two groups challenged the law: data-mining firms that sell prescriber data and an association of brand-name drug makers who use that data to tailor marketing visits to doctors. A federal district court upheld the law, the Second Circuit struck it down, and the Supreme Court reviewed the case.
Reasoning
The Court said the Vermont law singled out both a topic of speech (marketing about prescription drugs) and particular speakers (pharmaceutical manufacturers and detailers). That made the statute a content- and speaker-based restriction on expression, which requires heightened judicial scrutiny. The majority found Vermont’s privacy and cost-saving arguments insufficient because the law left the data widely available to many speakers and expressly allowed the State and other favored users to use the same information. Because the statute targeted disfavored speech and speakers and was not narrowly drawn to serve the asserted interests, the Court concluded the law could not survive heightened scrutiny and was unconstitutional.
Real world impact
The ruling prevents Vermont from enforcing its broad ban on the sale and marketing use of prescriber-identifying pharmacy records. Drug companies and data firms regain the ability to buy and use that data for targeted marketing; states seeking to limit such marketing must adopt different, narrower measures. The decision resolves a split among lower courts and affects similar state laws.
Dissents or concurrances
A dissent argued the law is ordinary commercial regulation that advances privacy, public health, and cost goals and should be reviewed under a more deferential commercial-speech standard; the dissent would have upheld the statute.
Opinions in this case:
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?